Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer
Interventions: RADIATION: Stereotactic Radiation|DRUG: Zimberelimab|DRUG: Sacituzumab govitecan
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Gilead Sciences